Maller R, Ahrne H, Eilard T, Eriksson I, Lausen I
Department of Infectious Diseases, University Hospital, Linköping, Sweden.
J Antimicrob Chemother. 1991 May;27 Suppl C:121-8. doi: 10.1093/jac/27.suppl_c.121.
Two hundred and twenty patients with serious infections verified or suspected to be of Gram-negative aetiology were treated in an open randomized comparative multicentre trial with amikacin 15 mg/kg/day given either as a single dose or in two divided doses at 12-h intervals. Amikacin was administered as a short-term iv infusion. When additional therapy was considered necessary piperacillin or ampicillin was recommended. The trial continues and an interim report on data from the 12 participating Scandinavian hospitals is presented. One hundred and forty-four patients have been evaluated for efficacy and 213 patients for safety. There were no significant differences between the two dosage regimens regarding efficacy and safety. A satisfactory clinical response was recorded in 129 (90%) of the evaluable patients. One serious adverse reaction was seen in a patient in the once-daily group. This was ototoxicity which was superimposed on a long standing hearing defect possibly caused by previous streptomycin therapy.
220例确诊或疑似革兰氏阴性菌病因严重感染的患者，在一项开放性随机对照多中心试验中接受治疗，试验使用阿米卡星，剂量为15mg/kg/天，给药方式为单次给药或每12小时分两次给药。阿米卡星采用短期静脉输注给药。当认为有必要进行额外治疗时，推荐使用哌拉西林或氨苄西林。试验仍在继续，现给出来自12家参与试验的斯堪的纳维亚医院数据的中期报告。144例患者接受了疗效评估，213例患者接受了安全性评估。两种给药方案在疗效和安全性方面无显著差异。129例（90%）可评估患者记录到满意的临床反应。每日一次给药组有1例患者出现严重不良反应。这是耳毒性，叠加在可能由先前链霉素治疗引起的长期听力缺陷之上。
